Prescription Influencer Shifts In India: Is Pharma Geared Up?

With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a conference in Mumbai hears.

Digital Health
Prescription Influence Moving Towards Auxiliary Stakeholders In India • Source: Shutterstock

Pharmaceutical companies will need to engage meaningfully with a broader stakeholder set in India, beyond just physicians, amid the growing influence of these groups in prescription decisions in the country. This at least is the major finding of a survey by management consultancy Bain & Company in collaboration with the Confederation of Indian Industry (CII).

While almost 80% of physicians covered in the Indian survey indicated that they find it challenging to keep pace with the breadth and the evolution of diseases and treatment protocols in view of the burden of infections and “tsunami” of non-communicable diseases, over 40% reported that drug formularies and insurance restrictions influence their

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By 

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.